The International Journal of Tuberculosis and Lung Disease

Gianni Acocella [Dedication]
pp. S281-S281(1)
Author: Roscigno, G.

Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications [Scientific Statement]
pp. S282-S283(2)
Author: Official Joint Statement of the International Union Against Tuberculosis and Lung Disease and the World Health Organization

Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers [Protocol]
pp. S284-S285(2)
Authors: International Union Against Tuberculosis and Lung Disease; World Health Organization

Fixed-dose combination formulations for tuberculosis treatment [Editorial]
pp. S286-S288(3)
Authors: Sbarbaro, John; Blomberg, Bjørn; Chaulet, Pierre

Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products
pp. S289-S291(3)
Author: Catalani, E.

Estimate of the global market for rifampicin-containing fixed-dose combination tablets
pp. S292-S300(9)
Authors: Norval, P.-Y.; Blomberg, B.; Kitler, M. E.; Dye, C.; Spinaci, S.

Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption
pp. S301-S308(8)
Authors: Ellard, G. A.; Fourie, P. B.

Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market
pp. S309-S316(8)
Authors: Pillai, G.; Fourie, P. B.; Padayatchi, N.; Onyebujoh, P. C.; McIlleron, H.; Smith, P. J.; Gabriels, G.

Panel Discussion I [Transcription of Panel Discussion]
pp. S317-S321(5)
Authors: Iseman, M D; Fourie, P B; Mitchison, D A; Kaul, C; Wang, J

The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency
pp. S322-S324(3)
Author: Ellard, G. A.

Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma
pp. S325-S328(4)
Authors: Smith, P. J.; van Dyk, J.; Fredericks, A.

The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability
pp. S329-S335(7)
Authors: McIlleron, H.; Gabriels, G.; Smith, P. J.; Fourie, P. B.; Ellard, G. A.

The WHO Simplified Study Protocol in practice: investigation of combined formulations supplied by the WHO
pp. S336-S342(7)
Authors: Panchagnula, R.; Kaur, K. J.; Singh, I.; Kaul, C. L.

The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules
pp. S343-S346(4)
Author: Ellard, G. A.

Detection of substandard fixed-dose combination tuberculosis drugs using thin-layer chromatography
pp. S347-S350(4)
Authors: Kenyon, T. A.; Kenyon, A. S.; Kgarebe, B. V.; Mothibedi, D.; Binkin, N. J.; Layloff, T. P.

Panel Discussion II [Transcription of Panel Discussion]
pp. S351-S352(2)
Authors: Iseman, M D; Fourie, P B; Mitchison, D A; Kaul, C; Wang, J

Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities
pp. S353-S357(5)
Author: Chaulet, P.

Requirements for anti-tuberculosis drug tender requests
pp. S358-S361(4)
Authors: Trébucq, Arnaud; Caudron, J. M.; Pinel, J.

Proposed minimum registration requirements for fixed-dose combination anti-tuberculosis drugs
pp. S362-S367(6)
Author: Fourie, P. B.

Structures required, roles and responsibilities in maintaining laboratories for quality assurance of anti-tuberculosis fixed-dose combinations in accordance with the IUATLD/WHO statement
pp. S368-S370(3)
Authors: Fourie, P. B.; Spinaci, S.

Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model?
pp. S371-S380(10)
Authors: Blomberg, B.; Kitler, M. E.; Milstien, J.; Dellepiane, N.; Fanning, A.; Norval, P. Y.; Spinaci, S.

Panel Discussion III [Transcription of Panel Discussion]
pp. S381-S387(7)
Authors: Iseman, M D; Spinaci, S; Weil, D; Coulibaly, I M; Cruz, R; Mantala, J

Eliano Catalani, 1935–1999 [In Memoriam]
pp. S388-S388(1)